Recombinant Mouse Prolyl endopeptidase FAP (Fap), partial

What is Recombinant Mouse Prolyl endopeptidase FAP and how does it function in physiological systems?

Recombinant Mouse Prolyl endopeptidase FAP (Fibroblast Activation Protein) is a cell surface glycoprotein serine protease that participates in extracellular matrix degradation. It exists in both membrane-bound and soluble forms, with the soluble form being functionally active in circulation. This protein is involved in numerous cellular processes including tissue remodeling, fibrosis, wound healing, inflammation, and tumor growth. The protein's functional significance stems from its dual enzymatic capabilities, exhibiting both post-proline cleaving endopeptidase activity and dipeptidyl peptidase activity .

The enzyme's endopeptidase activity shows marked preference for Ala/Ser-Gly-Pro-Ser/Asn/Ala consensus sequences, allowing it to cleave substrates such as alpha-2-antiplasmin SERPINF2 and SPRY2. Additionally, FAP can degrade gelatin and heat-denatured type I collagen, though it notably cannot degrade native collagen types I and IV, vibronectin, tenascin, laminin, fibronectin, fibrin, or casein .

How can researchers distinguish between FAP's endopeptidase activity and that of related enzymes?

Distinguishing FAP's endopeptidase activity from that of related enzymes, particularly prolyl endopeptidase (PREP), requires careful experimental design. Studies have demonstrated that FAP has a unique substrate specificity that can be leveraged for selective detection. A homogeneous fluorescence intensity assay based on FGF21, a natural FAP substrate, has proven effective in distinguishing FAP activity from other related enzymes .

When designing experiments to differentiate FAP activity, researchers should incorporate:

• FAP-selective peptide substrates containing the Gly-Pro consensus sequence

• Control peptides that lack this consensus sequence (e.g., peptides with Gly-Gly substitutions)

• Selective inhibitors like cpd60 for FAP and KYP-2047 for PREP

• Comparative analysis using wild-type, heterozygous, and Fap-deficient (KO) mouse samples

Research has shown that both FAP and PREP can cleave peptides containing the Gly-Pro motif, but FAP-deficient plasma still shows residual cleavage activity due to PREP. By using selective inhibitors at concentrations that provide specific inhibition of each enzyme, researchers can effectively differentiate between FAP and PREP activities .

What are the optimal methods for measuring Mouse FAP activity in different experimental contexts?

For quantitative measurement of Mouse FAP activity, researchers should consider context-specific methodological approaches:

For circulating FAP activity assessment, a homogeneous fluorescence intensity assay based on natural substrates like FGF21 provides high sensitivity and specificity. This method can effectively distinguish FAP's endopeptidase activity from related enzymes such as PREP. The assay utilizes peptide probes containing the Gly-Pro motif necessary for FAP cleavage, with control probes lacking this consensus sequence serving as negative controls .

For tissue samples, combining enzyme activity assays with selective inhibitors helps differentiate FAP activity from other proteases. Active site titration using tight-binding inhibitors like cpd60 enables determination of active enzyme concentration, which is crucial for accurate kinetic measurements. This approach revealed that mouse FAP exhibits lower catalytic efficiency than human FAP, primarily due to reduced kcat values, despite having higher relative concentration of active enzyme in typical preparations .

For mechanistic studies, researchers should include peptide substrates with controlled modifications that alter specificity. For example, modifications affecting the consensus sequence (Ala/Ser-Gly-Pro-Ser/Asn/Ala) can provide insights into substrate recognition mechanisms. The kinetics data shows that the kcat value remains essentially unchanged between parental (GP) and modified (aP) peptides, with the expected seven to eight-fold decrease in kcat/Km for aP cleavage .

How should researchers design experimental controls when working with recombinant Mouse FAP?

Robust experimental design for Mouse FAP research requires multiple layers of controls:

Genetic controls: Include samples from wild-type, heterozygous, and Fap-deficient (KO) mice. Studies have demonstrated that plasma from wild-type mice exhibits strong FAP activity, heterozygous mice show approximately half the activity, and homozygous Fap-KO mice display minimal activity. This genetic gradient provides validation of FAP-specific effects .

Substrate controls: Incorporate peptide substrates with and without the FAP cleavage motif. For example, peptides containing the Gly-Pro consensus sequence (GP probe) alongside control peptides where proline is replaced with glycine (GG probe) or using homologous regions of mouse FGF21 (EP probe) that lack the required consensus. This strategy helps distinguish FAP activity from other proteases .

Inhibitor controls: Employ selective inhibitors like cpd60 for FAP and KYP-2047 for PREP at concentrations providing selective inhibition of each enzyme. This approach enables differentiation between FAP and related protease activities .

Orthogonal validation: Combine activity assays with immunoblot analysis to correlate protein levels with enzymatic activity. Previous research has demonstrated that FAP is present in plasma from wild-type mice, reduced in heterozygotes, and undetectable in knockout mice, providing orthogonal confirmation of activity measurements .

How does Mouse FAP contribute to tumor progression and what experimental approaches can reveal these mechanisms?

Mouse FAP plays multifaceted roles in tumor progression through several distinct mechanisms that can be investigated using targeted experimental approaches:

Extracellular matrix remodeling: FAP enhances tumor growth progression by participating in extracellular matrix degradation. The plasma membrane form, in association with DPP4, PLAUR, or integrins, promotes cell adhesion, migration, and invasion through the ECM. To study this aspect, researchers can employ 3D invasion assays with FAP-expressing versus FAP-depleted cells, coupled with analysis of matrix degradation patterns .

Angiogenesis promotion: FAP enhances tumor growth by increasing angiogenesis. This effect can be studied using endothelial tube formation assays in the presence of FAP or FAP inhibitors, or through in vivo models examining vessel formation in tumors with varying FAP expression levels .

Immunosuppression: FAP reduces antitumor immune responses, contributing to tumor progression. Experimental approaches should include immune cell profiling in tumors with different FAP expression levels and functional assays measuring T-cell activation in the presence of FAP-expressing stromal cells .

Tissue-specific invasion: FAP promotes glioma cell invasion through the brain parenchyma by degrading the proteoglycan brevican. This mechanism can be studied using brain slice invasion assays with selective FAP inhibition or genetic manipulation .

Paradoxical tumor suppression: Interestingly, FAP can also act as a tumor suppressor in melanocytic cells through regulation of cell proliferation and survival in a serine protease activity-independent manner. This dual functionality necessitates careful experimental design that distinguishes between FAP's enzymatic and non-enzymatic functions, potentially through the use of catalytically inactive FAP mutants .

What are the kinetic differences between Mouse and Human FAP that researchers should consider in translational studies?

Researchers conducting translational studies involving both mouse and human FAP should be aware of significant kinetic differences that may impact experimental design and interpretation:

Mouse FAP exhibits lower catalytic efficiency compared to human FAP, primarily due to reduced kcat values. This fundamental difference was established through detailed kinetic analyses that controlled for variations in enzyme preparation quality. Active site titration using the tight-binding inhibitor cpd60 confirmed that mouse FAP preparations often contain a higher relative concentration of active enzyme, yet still demonstrate intrinsically weaker catalytic efficiency .

This species-specific difference has important implications for translational research:

• Dose adjustments: Higher concentrations of mouse FAP may be needed to achieve equivalent enzymatic activity levels compared to human FAP in experimental systems.

• Inhibitor efficacy: The differential kinetics may affect inhibitor binding and efficacy, requiring separate validation of inhibitors for each species.

• Substrate processing rates: Processing of natural substrates like FGF21 may occur at different rates between species, potentially affecting downstream signaling kinetics.

• Assay standardization: When comparing results between mouse models and human samples, researchers should normalize for these intrinsic differences in catalytic efficiency .

The specific kinetics data shows that while substrate binding affinity may be similar between species, the turnover rate differences result in distinct catalytic efficiencies that must be accounted for when designing translational experiments or interpreting comparative data .

How can researchers effectively distinguish between cell surface and soluble forms of FAP in experimental systems?

Distinguishing between cell surface-bound and soluble forms of FAP requires targeted methodological approaches that address their distinct characteristics while maintaining detection specificity:

Differential centrifugation: For in vitro systems, sequential centrifugation can separate membrane fractions (containing cell surface FAP) from soluble components. Cell lysates should undergo low-speed centrifugation to remove nuclei and cell debris, followed by high-speed ultracentrifugation (100,000g) to pellet membrane fractions. The resulting supernatant contains soluble FAP, while membrane-bound FAP resides in the pellet. Western blotting of both fractions using FAP-specific antibodies confirms distribution .

Activity-based detection: Both membrane-bound and soluble forms of FAP exhibit post-proline cleaving endopeptidase activity, but with potentially different accessibility to substrates. Researchers can exploit this by comparing activity in intact cells (primarily measuring cell surface activity) versus cell lysates or conditioned media (capturing total or soluble activity respectively). Selective inhibitors provide confirmation of FAP-specific activity .

Functional assessment: The plasma membrane form of FAP, in association with DPP4, PLAUR, or integrins, promotes cell adhesion, migration, and invasion through the ECM. Soluble FAP lacks these membrane associations but retains enzymatic activity. Researchers can design experiments that distinguish these functional differences, such as comparing matrix degradation patterns in cell-associated versus cell-free contexts .

Detection in biological fluids: For in vivo studies, the soluble form can be measured in plasma or other biological fluids using immunoassays or activity-based assays. Previous studies have demonstrated that FAP is present in plasma from wild-type mice, reduced in heterozygotes, and undetectable in knockout mice, providing valuable validation controls for such measurements .

What experimental training approaches can help researchers develop proficiency in FAP-related laboratory techniques?

Developing proficiency in FAP-related laboratory techniques requires a structured experimental training program that integrates theoretical knowledge with hands-on experience. Based on successful molecular pharmacology educational approaches, the following comprehensive training framework is recommended:

Theoretical foundation: Begin with instruction on FAP's structure, enzymatic mechanisms, physiological roles, and pathological implications. This knowledge provides the conceptual framework needed for experimental design and data interpretation .

Computational approaches: Incorporate molecular docking exercises that allow researchers to visualize FAP-substrate and FAP-inhibitor interactions. This computational component helps trainees understand structure-function relationships before proceeding to wet-lab experiments .

Target stability experiments: Implement drug affinity responsive target stability (DARTS) assays to assess FAP binding interactions. This technique allows researchers to evaluate how potential inhibitors or substrates affect FAP's susceptibility to proteolytic degradation, providing insights into binding-induced conformational changes .

Enzymatic activity assays: Train researchers in fluorescence-based activity assays using selective peptide substrates. Include comparisons between wild-type and mutant substrates to demonstrate specificity, and incorporate selective inhibitors to distinguish FAP activity from related proteases .

Live cell imaging: Utilize fluorescent probe detection of protein expression in living cells to visualize FAP localization and dynamics. This approach bridges biochemical assays with cellular context .

In vivo applications: When appropriate, extend training to include animal models that enable assessment of FAP expression and activity in physiologically relevant contexts .

Assessment methods: Evaluate proficiency through experimental reports that demonstrate understanding of principles, technical competence, and ability to interpret results. Complement this with recognition questionnaires that assess conceptual understanding .

This comprehensive training approach has been validated in educational settings, with results indicating that such programs promote understanding of research processes and increase motivation to learn among trainees .

What are the current limitations in FAP research and emerging approaches to address them?

Current FAP research faces several significant limitations that researchers are actively addressing through innovative methodological approaches:

Specificity challenges: Distinguishing FAP activity from other proline-specific proteases remains difficult. Recent advances include the development of homogeneous fluorescence intensity assays based on natural substrates like FGF21, which can effectively differentiate FAP endopeptidase activity from related enzymes such as PREP. Further refinement of selective substrates and inhibitors continues to improve specificity .

Contradictory functional roles: FAP demonstrates context-dependent effects, acting as both a tumor promoter in some cancers and a tumor suppressor in melanocytic cells. This apparent contradiction complicates therapeutic targeting and necessitates more nuanced research approaches. Emerging studies are focusing on tissue-specific and condition-specific factors that may determine FAP's functional outcome .

Translation between models: The kinetic differences between mouse and human FAP complicate translational research. Mouse FAP exhibits lower catalytic efficiency than human FAP despite often having higher concentrations of active enzyme in typical preparations. Researchers are developing normalization methods and species-specific parameters to facilitate more accurate translational studies .

Soluble versus membrane-bound functions: The differential functions of membrane-bound versus soluble FAP remain incompletely characterized. New approaches combining proteomics with functional assays are beginning to elucidate these distinct roles and their implications for disease processes .

Therapeutic targeting complexity: FAP's involvement in multiple physiological processes including wound healing and tissue remodeling creates challenges for therapeutic targeting. Emerging strategies include context-dependent delivery systems and temporary inhibition approaches that minimize off-target effects .

How can FAP research methodologies benefit from integration with other emerging technologies?

Integration of FAP research with emerging technologies offers promising opportunities to overcome current limitations and expand our understanding of this multifunctional protein:

Single-cell analysis: Incorporating single-cell RNA sequencing and proteomics can reveal cell-specific expression patterns of FAP in heterogeneous tissues like tumor microenvironments. This approach helps resolve contradictory findings by identifying specific cellular contexts where FAP promotes or inhibits disease progression .

Advanced imaging techniques: Multiplexed imaging methods combining FAP activity-based probes with markers of tissue remodeling, inflammation, or cell invasion provide spatial context for FAP function. These techniques can reveal localized activities that might be obscured in bulk tissue analyses .

CRISPR-based functional genomics: Systematic gene editing approaches allow precise manipulation of FAP and interacting partners to elucidate functional networks. This can help identify condition-specific factors determining whether FAP acts in a tumor-promoting or tumor-suppressing manner .

Computational prediction models: Machine learning approaches integrating structural, functional, and clinical data can help predict FAP substrate specificity and identify novel therapeutic targets. These computational methods complement experimental approaches by generating testable hypotheses and optimizing experimental design .

Biomarker development: The presence of soluble FAP in circulation suggests potential as a biomarker for conditions involving tissue remodeling or fibrosis. Advanced proteomics and glycomics methods can help identify FAP isoforms or post-translational modifications with enhanced diagnostic specificity .

Drug development platforms: High-throughput screening systems incorporating structure-based design principles can accelerate the development of selective FAP inhibitors with improved pharmacokinetic properties. These platforms benefit from the growing understanding of species-specific differences in FAP kinetics and binding properties .

By strategically integrating these technologies, researchers can develop more comprehensive models of FAP biology that account for its complex and sometimes contradictory functions across different physiological and pathological contexts.